| Clinical T Stage |
|
| T1c |
48% |
| T2a |
25% |
| T2b |
11% |
| T2c |
2.3% |
| T3 |
6.8% |
| T4 |
2.3% |
| Gleason Score |
|
| ≤ 6 |
36% |
| 7 |
17% |
| ≥ 8 |
47% |
| Median TRUS Volume (IQR) mL |
29.6 (22.2-45.3) |
| Median PSA Density (IQR) ng/mL2 |
0.33 (0.18-0.57) |
| Initial Treatment |
|
| Active Surveillance |
11% |
| Radical Prostatectomy |
18% |
| External Beam Radiation |
48% |
| Androgen Deprivation |
23% |
| Cancer Specific Mortality |
2% |
|
